Search Results

search

Search Filters

Organization
Priothera
Priothera-Logo (002).png
Priothera to Present Trial in Progress Poster for Mocravimod at 2024 American Society of Hematology (ASH) Annual Meeting
December 03, 2024 06:00 ET | Priothera
Mocravimod is being investigated in a global MO-TRANS Phase 3 study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation Mocravimod is the only S1P receptor...
Priothera-Logo (002).png
Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies
November 27, 2023 03:00 ET | Priothera
Mocravimod is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers Mocravimod is being investigated in a global registration-enabling Phase 3...
Priothera-Logo (002).png
Priothera cleared to begin Japanese arm of pivotal Phase 3 study with mocravimod in patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant
February 27, 2023 03:00 ET | Priothera
Mocravimod is the only S1PR modulator being developed as an adjunctive and maintenance treatment for blood cancers Dublin, Ireland – February 27th, 2023 – Priothera, a late-clinical stage...